Reported research findings
- No established independent human clinical trials define efficacy or safety for this specific analogue to date; the compound is newer than Semax and Selank.
BRAIN, FOCUS & MOOD RESEARCH
Adamax
A next-generation Semax analogue modified for greater stability, bioavailability, and potency.
Adamax is a synthetic analogue of Semax, modified with adamantane and N-acetyl groups for greater stability and potency. It is described as a highly potent nootropic research peptide. As a newer derivative, it does not yet have the independent clinical-study history of Semax or Selank.
Why BLP features Adamax
Included as a promising next-generation nootropic with an interesting modification for stability and potency. As a newer analogue, it lacks its own clinical-study history—so despite strong research interest it is presented honestly as experimental, distinct from the better-documented Semax and Selank.
Mechanism
Up-regulates BDNF and TrkB receptors, associated with neurogenesis.
Enhances dopamine and serotonin activity; boosts enkephalins and synaptic strength.
Adamantane modification is described as improving blood-brain-barrier crossing and extending half-life.
Activates cAMP/CREB pathways for neurotransmitter modulation.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- Mechanism inferred from the Semax family and the specific chemical modifications.
- Reported strong nootropic effects in research use, faster and stronger than standard Semax analogues.
Regulatory status
Adamax is investigational with minimal independent clinical evidence. Sold and offered strictly for laboratory and research use.